Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167540 · ClinicalTrials.gov registry record · Phase 1
GDNF Gene Therapy for Parkinson's Disease
A Phase 1 study of Parkinson's Disease, sponsored by Brain Neurotherapy Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 3
- Study locations
NCT04167540 is a Phase 1 study of Parkinson's Disease that is active but no longer recruiting, run by Brain Neurotherapy Bio. The registered enrollment target is 11 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04167540, a Phase 1 study of Parkinson's Disease, is active but no longer recruiting, sponsored by Brain Neurotherapy Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 3
- Study locations
Study Summary
The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
Conditions Studied
Interventions
- BIOLOGICAL AAV2-GDNF
Study Locations (3)
California
- University of California Irvine - Irvine
- University of California San Francisco - San Francisco
Ohio
- The Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167540
The ClinicalTrials.gov registry entry for NCT04167540 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (98% lower). The listed sponsor is Brain Neurotherapy Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which AAV2-GDNF is the first listed.
NCT04167540 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Ohio.
Frequently Asked Questions
What is clinical trial NCT04167540 about?
NCT04167540 is a clinical study titled "GDNF Gene Therapy for Parkinson's Disease". The objective of this Phase 1b investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a recent or a long-standing diagnosis of PD.
What is the current status of trial NCT04167540?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-04-01. Estimated completion is 2027-06.
What conditions does trial NCT04167540 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT04167540?
The interventions under investigation include: AAV2-GDNF (BIOLOGICAL).
Who is sponsoring clinical trial NCT04167540?
This trial is sponsored by Brain Neurotherapy Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04167540 being conducted?
This trial has 3 study locations across California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.